Modality
Small Molecule
MOA
PD-1i
Target
MALT1
Pathway
Wnt
CML
Development Pipeline
Preclinical
~May 2018
→ ~Aug 2019
Phase 1
Nov 2019
→ Sep 2028
Phase 1Current
NCT03585638
1,593 pts·CML
2019-11→2028-09·Terminated
1,593 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-09-022.4y awayPh2 Data· CML
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P1/2
Termina…
Catalysts
Ph2 Data
2028-09-02 · 2.4y away
CML
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03585638 | Phase 1/2 | CML | Terminated | 1593 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| BMY-7975 | Bristol-Myers Squibb | Phase 1 | MALT1 | |
| GSK-6516 | GSK | Phase 1/2 | MALT1 | |
| GSK-7987 | GSK | Phase 3 | MDM2 | |
| Nirabrutinib | BioNTech | Phase 2/3 | CDK2 | |
| BII-5240 | Biogen | Phase 2/3 | MALT1 | |
| ALN-3958 | Alnylam | Phase 2 | MALT1 | |
| Cevisacituzumab | Alnylam | Preclinical | MALT1 | |
| Cevinaritide | Genmab | Phase 2/3 | DLL3 | |
| ION-8812 | Ionis | Phase 1 | MALT1 |